TITLE

Retork completes system upgrade at Aventis plant

PUB. DATE
June 2000
SOURCE
Life Science Today;Jun2000, Vol. 1 Issue 3, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the completion of the end control system project by Rotork Control and Safety at the Aventis research facility. Expansion of the pilot-scale control system; Importance of Good Automated Manufacturing Practice guidelines for the ownership of the project; Start-up problems of the project.
ACCESSION #
9103585

 

Related Articles

  • ETHYPHARM TO DEVELOP A FLASH VERSION OF AVENTIS' ALLEGRA.  // Worldwide Biotech;Jul2002, Vol. 14 Issue 7, p6 

    Reports on a licensing agreement signed by Ethypharm with Aventis.

  • Aventis contributes $1 million to Red Cross.  // Pest Control;Feb2002, Vol. 70 Issue 2, p60 

    Reports the assistance of Aventis to the American Red Cross for the ongoing relief efforts following the terrorist attacks in Montvale, New Jersey.

  • Sanofi: Time not right to sell off beauty unit.  // WWD: Women's Wear Daily;9/8/1997, Vol. 174 Issue 48, p4 

    Focuses on pharmaceuticals and beauty products company, Sanofi's executive vice president for administration and finance, Jean-Paul Leon's issuance of a statement to clarify French business newspapers report that the company is planning to sell off its beauty division. Overview on Sanofi's...

  • Aventis promotes improved Dr. Chart program, MyDocOline software. Arnold, Matthew // Medical Marketing & Media;May2003, Vol. 38 Issue 5, p30 

    Reports on Aventis Inc.'s upgrade of its MyDocOnline software suite with the launch of Practice Solutions software. Automation of billing and prescribing functions; Expansion of the Dr. Chart program; Efforts to improve patient compliance.

  • Aventis Streamlines R&D. Houlton, Sarah // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p21 

    Reports on Aventis' plan to reduce its research and development costs by spinning out a stake in one of its research units. Plans of the private equity house Warburg Pincus to invest in ProSkelia; Aventis' plan to spin off its gene therapy unit, Gencell.

  • Beauty sales at Sanofi decline 2%.  // WWD: Women's Wear Daily;4/14/1995, Vol. 169 Issue 72, p9 

    Reports on the decline in sales of Sanofi SA's beauty products and fragrances during the first quarter of 1995.

  • Place your bets. Hawking, Stephen // New Scientist;6/22/2002, Vol. 174 Issue 2348, p50 

    Focuses on the Science Book Prize sponsored by Aventis. Citation of past winners; List of nominees; Details on several research cited by judges.

  • Aventis reveals divestment strategy and ends Bayer jv.  // European Chemical News;2/10/2003, Vol. 78 Issue 2039, p8 

    Reveals the divestment strategy of pharmaceutical firm Aventis. Details of its divestment activities; Information on its decision to end a joint venture deal with Rhodia and Bayer; Financial performance of Aventis.

  • Addition to rhizoctonia armoury for 2003 crop. Abel, Charles // Farmers Weekly;2/1/2002, Vol. 136 Issue 5, p60 

    Reports that Aventis SA hopes to introduce a rhizoctonia/black scurf seed treatment to potato growers in Great Britain.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics